benzatropine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
atropine derivatives 333 86-13-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • cogentin
  • benztropine mesilate
  • benzatropine
  • benztropine
  • tropine benzohydryl ether
  • benztropine mesylate
A centrally active muscarinic antagonist that has been used in the symptomatic treatment of PARKINSON DISEASE. Benztropine also inhibits the uptake of dopamine.
  • Molecular weight: 307.44
  • Formula: C21H25NO
  • CLOGP: 3.52
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 0
  • TPSA: 12.47
  • ALOGS: -5.41
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
2 mg O
2 mg P

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.21 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Hosey CM, Chan R, Benet LZ
BA (Bioavailability) 29 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
March 5, 1954 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Completed suicide 401.57 20.67 242 7831 145431 63335518
Toxicity to various agents 172.22 20.67 183 7890 247067 63233882
Psychotic disorder 151.10 20.67 71 8002 25641 63455308
Tardive dyskinesia 146.78 20.67 51 8022 8451 63472498
Granulocytopenia 146.00 20.67 46 8027 5626 63475323
Schizophrenia 142.65 20.67 52 8021 9900 63471049
Hallucination, auditory 96.18 20.67 42 8031 12782 63468167
Oculogyric crisis 88.99 20.67 24 8049 1697 63479252
Neuroleptic malignant syndrome 88.84 20.67 39 8034 12017 63468932
Paranoia 80.33 20.67 36 8037 11643 63469306
Akathisia 75.29 20.67 32 8041 9114 63471835
Muscle rigidity 71.37 20.67 33 8040 11467 63469482
Extrapyramidal disorder 69.83 20.67 34 8039 13250 63467699
Agitation 65.61 20.67 57 8016 59700 63421249
Sedation 61.73 20.67 46 8027 38763 63442186
Cardiac arrest 59.75 20.67 66 8007 92479 63388470
Catatonia 59.00 20.67 22 8051 4455 63476494
Dyskinesia 57.87 20.67 41 8032 31961 63448988
Clonus 54.65 20.67 21 8052 4615 63476334
Drooling 54.62 20.67 20 8053 3848 63477101
Myocarditis 52.98 20.67 26 8047 10299 63470650
Haemoglobin urine 52.65 20.67 10 8063 140 63480809
Drug interaction 51.53 20.67 99 7974 229032 63251917
Hyperreflexia 49.63 20.67 21 8052 5913 63475036
Ileus paralytic 47.94 20.67 19 8054 4532 63476417
Salivary hypersecretion 47.57 20.67 22 8051 7644 63473305
Tremor 46.83 20.67 70 8003 132169 63348780
Encephalitis autoimmune 46.48 20.67 14 8059 1472 63479477
Suicidal ideation 46.42 20.67 48 8025 62373 63418576
Dystonia 45.85 20.67 26 8047 13793 63467156
Schizoaffective disorder 45.10 20.67 17 8056 3545 63477404
Electrocardiogram QT prolonged 42.87 20.67 45 8028 59485 63421464
Abnormal behaviour 42.35 20.67 29 8044 21397 63459552
Hyperthermia 40.93 20.67 21 8052 9135 63471814
Postmortem blood drug level 40.72 20.67 8 8065 135 63480814
Red blood cells urine 39.44 20.67 10 8063 555 63480394
Eosinophil count abnormal 39.04 20.67 10 8063 578 63480371
Amaurosis 38.69 20.67 10 8063 599 63480350
Delusion 38.23 20.67 22 8051 11995 63468954
Treatment noncompliance 37.75 20.67 34 8039 37291 63443658
Death 34.32 20.67 115 7958 374266 63106683
Cardio-respiratory arrest 33.99 20.67 40 8033 59919 63421030
Antidepressant drug level above therapeutic 31.82 20.67 8 8065 429 63480520
Blood prolactin increased 31.31 20.67 13 8060 3490 63477459
Aggression 31.13 20.67 25 8048 23473 63457476
Psychiatric decompensation 30.46 20.67 10 8063 1391 63479558
Somnolence 29.39 20.67 68 8005 178617 63302332
Impulsive behaviour 29.26 20.67 10 8063 1573 63479376
Suspected suicide 29.17 20.67 15 8058 6553 63474396
Torsade de pointes 28.61 20.67 19 8054 13332 63467617
Arthralgia 26.87 20.67 20 8053 569690 62911259
Mental status changes 26.85 20.67 29 8044 39570 63441379
Food interaction 26.66 20.67 8 8065 830 63480119
Confusional state 26.58 20.67 78 7995 236302 63244647
Toxic encephalopathy 26.29 20.67 14 8059 6565 63474384
Restlessness 26.23 20.67 25 8048 29428 63451521
Mania 25.06 20.67 17 8056 12350 63468599
Pain 24.75 20.67 35 8038 740593 62740356
Pneumonia aspiration 24.66 20.67 26 8047 34514 63446435
Labelled drug-drug interaction issue 24.51 20.67 8 8065 1093 63479856
Grandiosity 24.39 20.67 6 8067 294 63480655
Hallucination 23.78 20.67 32 8041 54785 63426164
Mydriasis 23.19 20.67 16 8057 11940 63469009
Schizoaffective disorder bipolar type 23.14 20.67 5 8068 137 63480812
Facial paralysis 23.11 20.67 17 8056 14024 63466925
Mental impairment 22.99 20.67 17 8056 14134 63466815
Areflexia 22.68 20.67 10 8063 3108 63477841
Flat affect 22.35 20.67 8 8065 1442 63479507
Dysarthria 21.76 20.67 27 8046 42684 63438265
Unresponsive to stimuli 21.59 20.67 24 8049 33792 63447157

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Completed suicide 247.31 20.48 211 9628 97957 34849135
Granulocytopenia 201.16 20.48 74 9765 6493 34940599
Myocarditis 182.21 20.48 85 9754 13597 34933495
Toxicity to various agents 148.42 20.48 228 9611 200134 34746958
Tardive dyskinesia 147.40 20.48 57 9782 5733 34941359
Neuroleptic malignant syndrome 127.30 20.48 73 9766 17861 34929231
Cogwheel rigidity 110.25 20.48 32 9807 1320 34945772
Schizophrenia 106.61 20.48 51 9788 8615 34938477
Extrapyramidal disorder 101.06 20.48 56 9783 12824 34934268
Dystonia 92.97 20.48 50 9789 10795 34936297
Anticholinergic syndrome 85.87 20.48 26 9813 1243 34945849
Psychotic disorder 83.54 20.48 63 9776 24389 34922703
Hallucination, auditory 80.53 20.48 47 9792 11870 34935222
Head titubation 78.06 20.48 19 9820 392 34946700
Tremor 76.91 20.48 105 9734 82482 34864610
Agitation 70.87 20.48 84 9755 57315 34889777
Hyperprolactinaemia 68.00 20.48 23 9816 1573 34945519
Drug interaction 66.38 20.48 175 9664 225771 34721321
Sedation 64.91 20.48 51 9788 20955 34926137
Treatment noncompliance 61.64 20.48 56 9783 28044 34919048
Akathisia 60.17 20.48 34 9805 8075 34939017
Drug abuse 54.56 20.48 99 9740 98997 34848095
Galactorrhoea 52.01 20.48 14 9825 436 34946656
Drooling 51.23 20.48 23 9816 3359 34943733
Sinus tachycardia 51.17 20.48 41 9798 17319 34929773
Device leakage 49.95 20.48 28 9811 6547 34940545
Muscle rigidity 49.58 20.48 33 9806 10485 34936607
Product dose omission issue 47.16 20.48 104 9735 119607 34827485
Blood creatine phosphokinase increased 44.70 20.48 59 9780 44798 34902294
Abnormal behaviour 43.81 20.48 44 9795 24925 34922167
Parkinsonism 41.93 20.48 27 9812 8111 34938981
Restlessness 41.25 20.48 43 9796 25439 34921653
Sedation complication 39.96 20.48 16 9823 1761 34945331
Delusion 39.72 20.48 31 9808 12604 34934488
Delirium 39.49 20.48 55 9784 43936 34903156
Syringe issue 37.36 20.48 22 9817 5642 34941450
Priapism 37.21 20.48 21 9818 4973 34942119
Schizoaffective disorder 37.12 20.48 14 9825 1313 34945779
Dyskinesia 36.60 20.48 38 9801 22375 34924717
Serotonin syndrome 36.58 20.48 36 9803 19897 34927195
Mental status changes 34.75 20.48 48 9791 38035 34909057
Cerebral amyloid angiopathy 34.44 20.48 8 9831 134 34946958
Catatonia 34.41 20.48 20 9819 5005 34942087
Eosinophilic pleural effusion 33.98 20.48 9 9830 263 34946829
Aggression 33.90 20.48 48 9791 38916 34908176
Troponin increased 33.77 20.48 27 9812 11362 34935730
Dystonic tremor 30.99 20.48 8 9831 211 34946881
Antipsychotic drug level increased 30.83 20.48 17 9822 3848 34943244
Drug level increased 30.02 20.48 34 9805 22062 34925030
Rhabdomyolysis 30.00 20.48 62 9777 68101 34878991
Pericarditis 29.10 20.48 25 9814 11620 34935472
Inappropriate schedule of product administration 29.00 20.48 58 9781 62238 34884854
Blood prolactin increased 26.75 20.48 12 9827 1748 34945344
Hallucination 26.47 20.48 50 9789 51448 34895644
Blood pH decreased 26.47 20.48 13 9826 2321 34944771
Paranoia 26.34 20.48 24 9815 12044 34935048
Parasomnia 26.15 20.48 8 9831 396 34946696
Needle issue 25.86 20.48 18 9821 6147 34940945
Antipsychotic drug level decreased 25.83 20.48 10 9829 1007 34946085
Echocardiogram abnormal 25.40 20.48 10 9829 1053 34946039
Haemophagocytic lymphohistiocytosis 24.86 20.48 24 9815 12949 34934143
Tri-iodothyronine decreased 24.82 20.48 6 9833 120 34946972
Oculogyric crisis 24.70 20.48 11 9828 1575 34945517
Non-high-density lipoprotein cholesterol increased 24.11 20.48 6 9833 136 34946956
Gynaecomastia 23.71 20.48 21 9818 10159 34936933
Device malfunction 23.29 20.48 21 9818 10400 34936692
Unmasking of previously unidentified disease 23.26 20.48 9 9830 905 34946187
Agranulocytosis 23.20 20.48 31 9808 23790 34923302
Diarrhoea 23.09 20.48 47 9792 389865 34557227
Somnolence 22.86 20.48 76 9763 111040 34836052
Lethargy 22.48 20.48 41 9798 41081 34906011
Globulins increased 22.03 20.48 7 9832 393 34946699
Thyroxine decreased 21.53 20.48 6 9833 213 34946879
Globulins decreased 21.51 20.48 6 9833 214 34946878
Febrile neutropenia 21.42 20.48 6 9833 136843 34810249
Oedema peripheral 21.24 20.48 4 9835 119808 34827284
Faecaloma 20.93 20.48 15 9824 5362 34941730
Mania 20.93 20.48 19 9820 9492 34937600
Antipsychotic drug level above therapeutic 20.65 20.48 9 9830 1224 34945868
Muscle contracture 20.57 20.48 9 9830 1235 34945857
Disease progression 20.51 20.48 3 9836 108074 34839018

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Completed suicide 663.36 19.39 466 14518 245301 79484103
Granulocytopenia 357.33 19.39 118 14866 11313 79718091
Toxicity to various agents 299.73 19.39 381 14603 421159 79308245
Tardive dyskinesia 263.13 19.39 92 14892 10479 79718925
Myocarditis 214.64 19.39 97 14887 21636 79707768
Neuroleptic malignant syndrome 198.59 19.39 99 14885 27460 79701944
Schizophrenia 185.14 19.39 79 14905 15361 79714043
Psychotic disorder 171.16 19.39 103 14881 41299 79688105
Agitation 133.25 19.39 126 14858 99589 79629815
Hallucination, auditory 130.61 19.39 68 14916 20625 79708779
Drug interaction 115.48 19.39 246 14738 414937 79314467
Dystonia 111.74 19.39 62 14922 21337 79708067
Tremor 108.19 19.39 146 14838 169937 79559467
Extrapyramidal disorder 100.41 19.39 59 14925 22620 79706784
Muscle rigidity 99.44 19.39 56 14928 19826 79709578
Oculogyric crisis 94.31 19.39 31 14953 2921 79726483
Sedation 87.90 19.39 75 14909 51820 79677584
Catatonia 86.15 19.39 39 14945 8717 79720687
Treatment noncompliance 85.40 19.39 74 14910 52194 79677210
Cogwheel rigidity 81.15 19.39 28 14956 3060 79726344
Akathisia 79.19 19.39 42 14942 13217 79716187
Schizoaffective disorder 74.43 19.39 24 14960 2128 79727276
Paranoia 74.26 19.39 46 14938 19386 79710018
Device leakage 72.31 19.39 37 14947 10819 79718585
Drooling 69.91 19.39 30 14954 5904 79723500
Drug abuse 69.51 19.39 116 14868 162575 79566829
Dyskinesia 68.35 19.39 61 14923 44712 79684692
Delusion 67.22 19.39 44 14940 20379 79709025
Salivary hypersecretion 60.33 19.39 36 14948 14188 79715216
Product dose omission issue 59.97 19.39 139 14845 247398 79482006
Hyperprolactinaemia 59.61 19.39 25 14959 4651 79724753
Mental status changes 57.74 19.39 67 14917 66892 79662512
Aggression 56.13 19.39 58 14926 50900 79678504
Arthralgia 55.79 19.39 19 14965 571784 79157620
Syringe issue 55.54 19.39 26 14958 6272 79723132
Parkinsonism 55.24 19.39 36 14948 16548 79712856
Hallucination 55.04 19.39 74 14910 85671 79643733
Galactorrhoea 55.02 19.39 22 14962 3624 79725780
Restlessness 55.00 19.39 55 14929 46437 79682967
Abnormal behaviour 54.36 19.39 49 14935 36372 79693032
Death 53.38 19.39 229 14755 566285 79163119
Ileus paralytic 53.32 19.39 29 14955 9591 79719813
Anticholinergic syndrome 51.77 19.39 21 14963 3590 79725814
Blood creatine phosphokinase increased 50.19 19.39 62 14922 66028 79663376
Sinus tachycardia 49.93 19.39 47 14937 36861 79692543
Haemoglobin urine 47.92 19.39 10 14974 153 79729251
Cardio-respiratory arrest 47.15 19.39 78 14906 108432 79620972
Hyperreflexia 45.70 19.39 25 14959 8360 79721044
Pain 42.35 19.39 42 14942 703760 79025644
Diarrhoea 41.97 19.39 63 14921 880426 78848978
Clonus 41.78 19.39 22 14962 6818 79722586
Antipsychotic drug level increased 41.70 19.39 21 14963 5936 79723468
Priapism 40.97 19.39 19 14965 4486 79724918
Mania 40.69 19.39 31 14953 18229 79711175
Eosinophilic pleural effusion 40.63 19.39 10 14974 329 79729075
Intentional overdose 40.55 19.39 72 14912 105888 79623516
Joint swelling 39.89 19.39 4 14980 288642 79440762
Blood prolactin increased 39.88 19.39 18 14966 3993 79725411
Rhabdomyolysis 39.37 19.39 70 14914 103061 79626343
Head titubation 38.83 19.39 12 14972 926 79728478
Encephalitis autoimmune 38.68 19.39 15 14969 2279 79727125
Device malfunction 38.36 19.39 32 14952 21416 79707988
Anaemia 38.12 19.39 18 14966 444997 79284407
Needle issue 37.83 19.39 26 14958 13042 79716362
Suicidal ideation 37.44 19.39 58 14926 76282 79653122
Delirium 36.98 19.39 61 14923 84566 79644838
Gynaecomastia 36.69 19.39 21 14963 7660 79721744
Antipsychotic drug level above therapeutic 36.50 19.39 14 14970 2066 79727338
Somnolence 35.42 19.39 112 14872 238869 79490535
Suspected suicide 35.32 19.39 23 14961 10553 79718851
Cardiac arrest 34.57 19.39 90 14894 172006 79557398
Dystonic tremor 34.20 19.39 8 14976 211 79729193
Dysarthria 34.03 19.39 52 14932 67570 79661834
Red blood cells urine 33.26 19.39 10 14974 703 79728701
Eosinophil count abnormal 32.75 19.39 10 14974 741 79728663
Confusional state 32.55 19.39 132 14852 317865 79411539
Inappropriate schedule of product administration 32.26 19.39 75 14909 133553 79595851
Respiratory arrest 31.46 19.39 46 14938 57504 79671900
Psychiatric decompensation 30.80 19.39 15 14969 3948 79725456
Persecutory delusion 30.58 19.39 16 14968 4893 79724511
Cerebral amyloid angiopathy 30.55 19.39 8 14976 339 79729065
Tachycardia 29.78 19.39 87 14897 177681 79551723
Drug level increased 29.78 19.39 37 14947 39614 79689790
Agranulocytosis 29.09 19.39 39 14945 44991 79684413
Amaurosis 28.22 19.39 10 14974 1181 79728223
Electroconvulsive therapy 28.21 19.39 6 14978 101 79729303
Unresponsive to stimuli 28.21 19.39 43 14941 55745 79673659
Parasomnia 26.74 19.39 8 14976 553 79728851
Leukopenia 26.61 19.39 64 14920 116449 79612955
White blood cell count increased 26.37 19.39 49 14935 74584 79654820
Overdose 26.07 19.39 85 14899 184121 79545283
Postmortem blood drug level 25.78 19.39 7 14977 341 79729063
Mental impairment 25.28 19.39 24 14960 19012 79710392
Fatigue 25.25 19.39 90 14894 929637 78799767
Oedema peripheral 25.22 19.39 8 14976 252280 79477124
Hypersensitivity 23.38 19.39 10 14974 262229 79467175
Dyspnoea 23.23 19.39 83 14901 856942 78872462
Electrocardiogram QT prolonged 23.21 19.39 52 14932 90334 79639070
Autonomic nervous system imbalance 23.03 19.39 13 14971 4617 79724787
Neutrophil count increased 22.99 19.39 28 14956 29368 79700036
Mydriasis 22.96 19.39 22 14962 17621 79711783
Haemophagocytic lymphohistiocytosis 22.51 19.39 24 14960 21813 79707591
Disease progression 22.04 19.39 4 14980 184358 79545046
Alopecia 21.97 19.39 8 14976 231347 79498057
Muscle contracture 21.78 19.39 10 14974 2307 79727097
Mental disorder 21.59 19.39 28 14956 31274 79698130
Non-high-density lipoprotein cholesterol increased 21.30 19.39 6 14978 335 79729069
Antidepressant drug level above therapeutic 21.19 19.39 7 14977 669 79728735
Gait disturbance 21.09 19.39 86 14898 207420 79521984
Clang associations 21.02 19.39 4 14980 37 79729367
Headache 20.71 19.39 59 14925 653713 79075691
Hyperthermia 20.70 19.39 21 14963 18016 79711388
Antipsychotic drug level below therapeutic 20.54 19.39 8 14976 1230 79728174
Febrile neutropenia 20.28 19.39 9 14975 230990 79498414
Blood pH decreased 20.17 19.39 12 14972 4699 79724705
Pneumonia aspiration 20.04 19.39 41 14943 66926 79662478
Peripheral swelling 20.03 19.39 13 14971 269604 79459800
Swelling 19.74 19.39 8 14976 216703 79512701
Unmasking of previously unidentified disease 19.72 19.39 9 14975 2048 79727356
Troponin increased 19.56 19.39 21 14963 19234 79710170
Neutropenia 19.52 19.39 106 14878 287604 79441800
Disorganised speech 19.47 19.39 9 14975 2108 79727296
General physical health deterioration 19.47 19.39 14 14970 275224 79454180
Nephrogenic diabetes insipidus 19.40 19.39 9 14975 2125 79727279
Pain in extremity 19.39 19.39 24 14960 364514 79364890

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N04AC01 NERVOUS SYSTEM
ANTI-PARKINSON DRUGS
ANTICHOLINERGIC AGENTS
Ethers of tropine or tropine derivatives
FDA MoA N0000000207 Histamine Receptor Antagonists
FDA MoA N0000175370 Cholinergic Antagonists
FDA EPC N0000175574 Anticholinergic
CHEBI has role CHEBI:48407 antiparkinson agent
CHEBI has role CHEBI:48876 muscarinic antagonists
CHEBI has role CHEBI:50370 parasympatholytics
CHEBI has role CHEBI:66956 antidyskinetic agent
CHEBI has role CHEBI:146270 oneirogens
CHEBI has role CHEBI:149553 anticoronaviral drug
MeSH PA D018726 Anti-Dyskinesia Agents
MeSH PA D000978 Antiparkinson Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D018678 Cholinergic Agents
MeSH PA D018680 Cholinergic Antagonists
MeSH PA D015259 Dopamine Agents
MeSH PA D018765 Dopamine Uptake Inhibitors
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D018727 Muscarinic Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D014179 Neurotransmitter Uptake Inhibitors
MeSH PA D010276 Parasympatholytics
MeSH PA D018373 Peripheral Nervous System Agents
FDA EPC N0000175750 Antihistamine

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Postencephalitic parkinsonism indication 19972008 DOID:14332
Parkinsonism indication 32798002
Parkinson's disease indication 49049000 DOID:14330
Extrapyramidal disease indication 76349003
Arteriosclerotic Parkinsonism indication
Urinary tract obstruction contraindication 7163005 DOID:5200
Chronic obstructive lung disease contraindication 13645005 DOID:3083
Severe chronic ulcerative colitis contraindication 14311001
Disorder of autonomic nervous system contraindication 15241006
Toxic megacolon contraindication 28536002 DOID:1770
Atony of colon contraindication 29479008
Shigellosis contraindication 36188001
Hypertensive disorder contraindication 38341003 DOID:10763
Conduction disorder of the heart contraindication 44808001
Low blood pressure contraindication 45007003
Achalasia of esophagus contraindication 45564002 DOID:9164
Chronic heart failure contraindication 48447003
Dysuria contraindication 49650001
Paralytic ileus contraindication 55525008 DOID:8442
Ulcerative colitis contraindication 64766004 DOID:8577
Hiatal hernia contraindication 84089009 DOID:12642
Open-angle glaucoma contraindication 84494001 DOID:1067
Kidney disease contraindication 90708001 DOID:557
Thyrotoxicosis contraindication 90739004 DOID:7997
Myasthenia gravis contraindication 91637004 DOID:437
Tardive dyskinesia contraindication 102449007
Dysentery contraindication 111939009
Gastrointestinal obstruction contraindication 126765001
Bleeding contraindication 131148009
Gastroesophageal reflux disease contraindication 235595009 DOID:8534
Disease of liver contraindication 235856003 DOID:409
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Fever contraindication 386661006
Angle-closure glaucoma contraindication 392291006 DOID:13550
Pseudomembranous enterocolitis contraindication 397683000
Gastric ulcer contraindication 397825006 DOID:10808
Disorder of coronary artery contraindication 414024009




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.86 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Muscarinic acetylcholine receptor M1 GPCR ANTAGONIST Ki 9.64 WOMBAT-PK CHEMBL
Alpha-2A adrenergic receptor GPCR Ki 6.69 DRUG MATRIX
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 7.23 DRUG MATRIX
Sodium-dependent serotonin transporter Transporter IC50 4.62 CHEMBL
Sodium-dependent noradrenaline transporter Transporter Ki 5.86 DRUG MATRIX
5-hydroxytryptamine receptor 2B GPCR Ki 6.90 DRUG MATRIX
5-hydroxytryptamine receptor 2C GPCR Ki 7.50 DRUG MATRIX
5-hydroxytryptamine receptor 6 GPCR Ki 5.89 DRUG MATRIX
Alpha-2B adrenergic receptor GPCR Ki 7.52 DRUG MATRIX
D(3) dopamine receptor GPCR Ki 6.65 DRUG MATRIX
Histamine H1 receptor GPCR Ki 8.96 WOMBAT-PK
Histamine H2 receptor GPCR Ki 5.93 DRUG MATRIX
Muscarinic acetylcholine receptor M2 GPCR ANTAGONIST Ki 8.85 WOMBAT-PK
Muscarinic acetylcholine receptor M3 GPCR ANTAGONIST Ki 8.96 WOMBAT-PK
Muscarinic acetylcholine receptor M4 GPCR ANTAGONIST Ki 8.96 WOMBAT-PK
Muscarinic acetylcholine receptor M5 GPCR ANTAGONIST Ki 8.55 WOMBAT-PK
Alpha-2C adrenergic receptor GPCR Ki 7.24 DRUG MATRIX
Sodium-dependent dopamine transporter Transporter Kd 7.25 WOMBAT-PK
Alpha-1D adrenergic receptor GPCR Ki 7.59 DRUG MATRIX
5-hydroxytryptamine receptor 2A GPCR Ki 8.16 DRUG MATRIX
Sodium-dependent neutral amino acid transporter B(0)AT1 Transporter INHIBITOR IC50 4.36 IUPHAR
Alpha-1B adrenergic receptor GPCR Ki 7.39 DRUG MATRIX
Membrane-associated progesterone receptor component 1 Membrane receptor Ki 6.95 DRUG MATRIX
Alpha-1A adrenergic receptor GPCR IC50 6.85 CHEMBL
Muscarinic acetylcholine receptor M2 GPCR Ki 8.59 CHEMBL
Muscarinic acetylcholine receptor M1 GPCR Ki 9.23 CHEMBL
Sodium-dependent serotonin transporter Transporter Ki 5.29 CHEMBL
Sodium-dependent dopamine transporter Transporter Ki 6.93 CHEMBL

External reference:

IDSource
D00778 KEGG_DRUG
132-17-2 SECONDARY_CAS_RN
1424 RXNORM
C0005098 UMLSCUI
CHEBI:3048 CHEBI
CXQ PDB_CHEM_ID
CHEMBL1201203 ChEMBL_ID
CHEMBL1200383 ChEMBL_ID
DB00245 DRUGBANK_ID
7601 IUPHAR_LIGAND_ID
1201549 PUBCHEM_CID
3130 MMSL
4264 MMSL
563 MMSL
d00175 MMSL
29527005 SNOMEDCT_US
372846002 SNOMEDCT_US
77390008 SNOMEDCT_US
D001590 MESH_DESCRIPTOR_UI
292 INN_ID
4017824 VANDF
4019630 VANDF
1NHL2J4X8K UNII
001647 NDDF
004667 NDDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Benztropine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0143-9233 INJECTION 1 mg INTRAMUSCULAR ANDA 15 sections
Benztropine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0143-9729 INJECTION 1 mg INTRAMUSCULAR ANDA 14 sections
Benztropine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0143-9729 INJECTION 1 mg INTRAMUSCULAR ANDA 14 sections
Benztropine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0603-2433 TABLET 0.50 mg ORAL ANDA 16 sections
Benztropine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0603-2434 TABLET 1 mg ORAL ANDA 16 sections
Benztropine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0603-2435 TABLET 2 mg ORAL ANDA 16 sections
Benztropine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0603-2437 TABLET 0.50 mg ORAL ANDA 16 sections
Benztropine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0603-2437 TABLET 0.50 mg ORAL ANDA 16 sections
Benztropine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0603-2437 TABLET 0.50 mg ORAL ANDA 16 sections
Benztropine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0603-2438 TABLET 1 mg ORAL ANDA 16 sections
Benztropine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0603-2438 TABLET 1 mg ORAL ANDA 16 sections
Benztropine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0603-2438 TABLET 1 mg ORAL ANDA 16 sections
Benztropine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0603-2439 TABLET 2 mg ORAL ANDA 16 sections
Benztropine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0603-2439 TABLET 2 mg ORAL ANDA 16 sections
Benztropine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0603-2439 TABLET 2 mg ORAL ANDA 16 sections
Benztropine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0615-8210 TABLET 0.50 mg ORAL ANDA 16 sections
Benztropine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0615-8211 TABLET 1 mg ORAL ANDA 16 sections
Benztropine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0615-8222 TABLET 0.50 mg ORAL ANDA 16 sections
Benztropine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0615-8223 TABLET 1 mg ORAL ANDA 16 sections
benztropine mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0615-8352 TABLET 2 mg ORAL ANDA 16 sections
Benztropine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0615-8478 TABLET 2 mg ORAL ANDA 16 sections
Benztropine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0832-1080 TABLET 0.50 mg ORAL ANDA 15 sections
Benztropine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0832-1081 TABLET 1 mg ORAL ANDA 15 sections
Benztropine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0832-1082 TABLET 2 mg ORAL ANDA 15 sections
Benztropine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0904-6788 TABLET 0.50 mg ORAL ANDA 16 sections
Benztropine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0904-6789 TABLET 2 mg ORAL ANDA 16 sections
Benztropine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0904-6790 TABLET 1 mg ORAL ANDA 16 sections
Benztropine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0904-7288 TABLET 0.50 mg ORAL ANDA 16 sections
Benztropine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0904-7289 TABLET 1 mg ORAL ANDA 16 sections
Benztropine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0904-7290 TABLET 2 mg ORAL ANDA 16 sections